Misdiagnosis of stroke in tissue plasminogen activator-treated patients: Characteristics and outcomes

被引:90
作者
Scott, PA [1 ]
Silbergleit, R [1 ]
机构
[1] Univ Michigan, Dept Emergency Med, Ann Arbor, MI 48109 USA
关键词
D O I
10.1016/S0196-0644(03)00443-8
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objective: Misdiagnosis of acute ischemic stroke is a risk inherent in treating patients with acute deficits, yet few data exist on the problem. We report an evaluation of emergency department misdiagnoses in patients treated with tissue plasminogen activator for acute ischemic stroke. Methods: We conducted an observational study of 151 consecutive patients treated without an acute stroke team. Initial diagnosis was compared with interim and hospital discharge diagnoses. Separate analyses were performed for patients without a final diagnosis of acute ischemic stroke and for those without a final diagnosis of either acute ischemic stroke or transient ischemic attack, combined. Results: Ten of 151 patients (7%; 95% confidence interval [Cl] 3% to 12%) had final diagnoses that did not include acute ischemic stroke. Six of 151 (4%; 95% Cl 11% to 8%) had a final diagnosis other than acute ischemic stroke or transient ischemic attack (conversion disorder [41, complex migraine [1], and Todd's paralysis [1]). These "stroke mimics" had no intracranial hemorrhage (0%; 95% Cl 0% to 31%), had less disability at discharge (modified Rankin Scale score mean SD, 2.2 +/- 1.3 versus 3.2 +/- 1.8), and were younger +/-mean age SD, 47 +/- 21 years versus 68 +/- 15 years) than patients with acute ischemic stroke or transient ischemic attack. An additional 4 (3%) patients had interim diagnoses other than acute ischemic stroke, all subsequently changed to acute ischemic stroke after magnetic resonance imaging or computed tomography. Conclusion: These data show that in a 4-hospital system without an acute stroke team, thrombolytic treatment of patients with diagnoses mimicking stroke was infrequent, and hemorrhagic complications did not occur in any patients without an acute ischemic stroke. However, because the number of mimics was small, safety cannot be ensured with statistical confidence.
引用
收藏
页码:611 / 618
页数:8
相关论文
共 24 条
[1]   Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke - A statement for healthcare professionals from a special writing group of the stroke council, American Heart Association [J].
Adams, HP ;
Brott, TG ;
Furlan, AJ ;
Gomez, CR ;
Grotta, J ;
Helgason, CM ;
Kwiatkowski, T ;
Lyden, PD ;
Marler, JR ;
Torner, J ;
Feinberg, W ;
Mayberg, M ;
Thies, W .
CIRCULATION, 1996, 94 (05) :1167-1174
[2]   Intravenous tissue-type plasminogen activator for treatment of acute stroke - The standard treatment with alteplase to reverse stroke (STARS) study [J].
Albers, GW ;
Bates, VE ;
Clark, WM ;
Bell, R ;
Verro, P ;
Hamilton, SA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (09) :1145-1150
[3]   Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke [J].
Brott, T ;
Broderick, J ;
Kothari, R ;
ODonoghue, M ;
Barsan, W ;
Tomsick, T ;
Spilker, J ;
Miller, R ;
Sauerbeck, L ;
Farrell, J ;
Kelly, J ;
Perkins, T ;
Miller, R ;
McDonald, T ;
Rorick, M ;
Hickey, C ;
Armitage, J ;
Perry, C ;
Thalinger, K ;
Rhude, R ;
Schill, J ;
Becker, PS ;
Heath, RS ;
Adams, D ;
Reed, R ;
Klei, M ;
Hughes, A ;
Anthony, J ;
Baudendistel, D ;
Zadicoff, C ;
Rymer, M ;
Bettinger, I ;
Laubinger, P ;
Schmerler, M ;
Meiros, G ;
Lyden, P ;
Dunford, J ;
Zivin, J ;
Rapp, K ;
Babcock, T ;
Daum, P ;
Persona, D ;
Brody, M ;
Jackson, C ;
Lewis, S ;
Liss, J ;
Mahdavi, Z ;
Rothrock, J ;
Tom, T ;
Zweifler, R .
STROKE, 1997, 28 (11) :2109-2118
[4]   Effectiveness of t-PA in acute ischemic stroke - Outcome relates to appropriateness [J].
Buchan, AM ;
Barber, PA ;
Newcommon, N ;
Karbalai, HG ;
Demchuk, AM ;
Hoyte, KM ;
Klein, GM ;
Feasby, TE .
NEUROLOGY, 2000, 54 (03) :679-684
[5]   MINIMIZING THE RISK OF INAPPROPRIATELY ADMINISTERING THROMBOLYTIC THERAPY (THROMBOLYSIS AND ANGIOPLASTY IN MYOCARDIAL-INFARCTION [TAMI] STUDY-GROUP) [J].
CHAPMAN, GD ;
OHMAN, M ;
TOPOL, EJ ;
CANDELA, RJ ;
KEREIAKES, DJ ;
SAMAHA, J ;
BERRIOS, E ;
PIEPER, KS ;
YOUNG, SY ;
CALIFF, RM .
AMERICAN JOURNAL OF CARDIOLOGY, 1993, 71 (10) :783-787
[6]   Intravenous tissue plasminogen activator for acute ischemic stroke - A Canadian hospital's experience [J].
Chapman, KM ;
Woolfenden, AR ;
Graeb, D ;
Johnston, DCC ;
Beckman, J ;
Schulzer, M ;
Teal, PA .
STROKE, 2000, 31 (12) :2920-2924
[7]   Intravenous tissue plasminogen activator for acute ischemic stroke: Feasibility, safety, and efficacy in the first year of clinical practice [J].
Chiu, D ;
Krieger, D ;
Villar-Cordova, C ;
Kasner, SE ;
Morgenstern, B ;
Bratina, PL ;
Yatsu, FM ;
Grotta, JC .
STROKE, 1998, 29 (01) :303-303
[8]   Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial [J].
Clark, WM ;
Wissman, S ;
Albers, GW ;
Jhamandas, JH ;
Madden, KP ;
Hamilton, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2019-2026
[9]   Diagnosis of stroke by the nonneurologist - A validation study [J].
Ferro, JM ;
Pinto, AN ;
Falcao, I ;
Rodrigues, G ;
Ferreira, J ;
Falcao, F ;
Azevedo, E ;
Canhao, P ;
Melo, TP ;
Rosas, MJ ;
Oliveira, V ;
Salgado, AV .
STROKE, 1998, 29 (06) :1106-1109
[10]   Early intravenous thrombolysis with recombinant tissue-type plasminogen activator in vertebrobasilar ischemic stroke [J].
Grond, M ;
Rudolf, J ;
Schmülling, S ;
Stenzel, C ;
Neveling, M ;
Heiss, WD .
ARCHIVES OF NEUROLOGY, 1998, 55 (04) :466-469